An Act to Require
Maine Legislature, Session 132, LD 0582
Committee Amendment CA_A_S63 (Senate)

"A"
• COMMITTEE AMENDMENT ".A " to S.P, 265, L.D, 582, "An Act to Require
Health Insurance Carriers to Provide Coverage for Blood Testing for Perfluoroalkyl and
Polyfluoroalkyl Substances"
Amend the bill in section I in §4320-W by striking out all of subsection 3 (page I, lines
14 to 19 in L.D.).
Amend the bill by striking out all of section 2.
Amend the bill in section 3 in the 3rd line (page 1, line 30 in L.D.) by striking out the
following; "2026" and inserting the following: '2027'
.17 Amend the bill by inserting after section 3 the following;
'See. 4. Exemption from mandate review. Notwithstanding (lie Maine R.evised
Statutes, Title 24-A, section 2752, this Act is enacted without review and evaluation by the
' Department of Professional and Financial Regulation, Bureau of Insurance,
Sec. 5. Appropriations and allocations. The following appropriations and
allocations are made,
ADMINISTRATIVE AND FINANCIAL SERVICES, DEPARTMENT OF
State Benetit Mandate Defrayal Z373
Initiative: Provides ongoing funding for the cost of the benefit mandate providing coverage
of blood testing-for perfluoroalkyl and polyfluoroalkyl substances, beginning January I,
2027.
GENERAL FUND 2025-26 2026-27
AIIOlher $0 $90,000
GENERAL FUND TOTAL $0 $90,000
Page I - 132LR0980(02)
COMMITTEE AMENDMENT
COMMITTEE AMENDMENT-^ " to S.P. 265, L.D. 582 (5- [o^
I Amend the bill by relettering or renumbering any noncoiisecutive Part letter or section
number to read consecutively.
SUMMARY
This amendment, which is the majority report of the committee, does the following.
!. It strikes the provision in the bill that j)roliibits a health insurance carrier from
imposing cost-sharing for coverage for blood testing for perfluoroalkyl and polyfluoroalkyl
substances,
2. It strikes the unallocated language section in the bill stating the Legislature's Finding
that Ihe coverage required in the bill is not an expansion of the State's essential health
benefits.
3, It changes the application date for the coverage requiremeiU From January 1, 2026
to January 1,2027.
4, It adds language exempting the bill from review and evaluation by the Department
of Professional and Financial Regulation, Bureau of Insurance,
5, It adds an appropriations and allocations section,
FISCAL NOTE REQUmED
(See attached)
COMMITTEE AMENDMENT
Revised; 04/29/25 t-KI-
LD 582 LR 980(02)
An Act to Require Health Insurance Carriers to Provide Coverage for Blood Testing for
Perfluoronlkyl and Polyfluoroalkyl Substances
Fiscal Note for Bill as Amended by Committee Amendment "^ ^$"(e^>
Committee: Health Coverage, Tnsurancc and Financial Services
Fiscal Note Required: Yes
Fiscal Note
Projections Projections
FY 2025-26 FY 2026-27 FY 2027-28 FY 2028-29
Net Cost (Savings)
General Fund
Highway Fund
Appropriations/Allocations
General Fund
Highway Fund
Fiscal Detail and Notes
This bill requires carriers offering health plans in this State to provide coverage for blood testing for perfluoroalkyl
and polyfluoroalkyl substances. The requirements of the bill apply to health plans issued or renewed on or after
January 1, 2027. The bill includes General Fund appropriations to the Department of Administrative and Financial
Services of $90,000 for the estimated cost to reimburse the insurance carriers, for 6 months of the State's defrayal cost
of this new mandate, The mandate will go into effect on all health insurance plans on (lie marketplace beginning
January 1,2027 and is estimated to cost $180,000 annually, thereafter.
The State Employee Health Plan's first impacted plan year will be fiscal year 2027-28 and is estimated to cost $57,313
annually thereafter. The costs are split across the General Fund ($26,364), Highway Fund ($9,170) and all other fluids
($21,779).
$0
so
$0
$0
$90,000
$0
$90,000
$0
$206,364
$9,170
$206,364
$9,170
$206,364
$9,170
$206,364
$9,170
LR0980(02) - Fiscal Note - Page 1 of 1